China Resources Pharmaceutical Group Limited

China Resources Pharmaceutical Group Limited (CR Pharma) is an integrated pharmaceutical company involved in the manufacturing, distribution, and retail of pharmaceutical and healthcare products. The company was established in 2000 as a subsidiary of China Resources (Holdings) Company Limited, a state-owned enterprise. It went public in 2016, listing on the Hong Kong Stock Exchange.

CR Pharma's business is structured into three main segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, and Pharmaceutical Retail. The manufacturing division develops and produces a wide range of products, including chemical drugs, traditional Chinese medicines, biological products, and healthcare supplements. Its product portfolio addresses various therapeutic areas such as cardiovascular diseases, respiratory illnesses, and gastroenterology. The distribution segment, which accounts for over 80% of total revenue, provides logistics, marketing, and supply chain solutions to manufacturers, hospitals, and other distributors. The retail segment operates a chain of pharmacies under brands like Teck Soon Hong.

The company's revenue is primarily generated from its distribution services, followed by manufacturing and retail sales. CR Pharma is considered one of the top three pharmaceutical distributors in China by revenue. The company has grown through strategic acquisitions and investments in research and development, aiming to expand its product portfolio and distribution network across China.

Keywords: pharmaceutical manufacturing, pharmaceutical distribution, pharmaceutical retail, healthcare products, traditional Chinese medicine, chemical drugs, biological drugs, supply chain logistics, China healthcare, over-the-counter drugs, prescription drugs, R&D, clinical services, cardiovascular, respiratory, gastroenterology, nutritional products, medical distribution, pharmacy chain